Imatinib Mesylate (Gleevec™) for the Treatment of Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours: A Clinical Practice Guideline

This is a clinical practice guideline for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours. The guideline states that unresectable or metastatic gastrointestinal stromal tumours are often resistant to traditional methods of treatment like conventional chemotherapy. As such, the guideline focuses on the benefits and harms of imatinib mesylate as a form of treatment. The guideline therefore considers whether treatment with imatinib mesylate has a benefit in terms of tumour response, disease progression, survival or quality of life.